News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,918 Results
Type
Article (13486)
Company Profile (103)
Press Release (245329)
Section
Business (87826)
Career Advice (460)
Deals (15316)
Drug Delivery (60)
Drug Development (36467)
Employer Resources (49)
FDA (6234)
Job Trends (6178)
News (149738)
Policy (13992)
Tag
Academia (435)
Africa (312)
Alliances (23036)
Alzheimer's disease (322)
Approvals (6215)
Arizona (35)
Artificial intelligence (40)
Asia (19635)
Australia (2532)
Bankruptcy (143)
Best Places to Work (4199)
Biosimilars (31)
Biotechnology (41)
C2C Services and Suppliers (10601)
California (594)
Canada (433)
Cancer (141)
Career advice (402)
Cell therapy (23)
China (66)
Clinical research (30046)
Collaboration (51)
Compensation (24)
Connecticut (24)
COVID-19 (737)
Cystic fibrosis (21)
Data (98)
Diabetes (26)
Diagnostics (1201)
Drug pricing (47)
Earnings (31139)
Employer resources (43)
Europe (38393)
Events (36261)
Executive appointments (83)
FDA (6299)
Florida (74)
Funding (37)
Gene therapy (40)
GLP-1 (259)
Government (1249)
Healthcare (3503)
Hotbed/Location (177915)
Illinois (68)
Indiana (59)
Infectious disease (741)
Inflammatory bowel disease (40)
Interviews (57)
IPO (5781)
IRA (22)
Job creations (2046)
Job search strategy (371)
Kansas (49)
Layoffs (164)
Legal (3398)
Lung cancer (31)
Manufacturing (45)
Maryland (88)
Massachusetts (521)
Medical device (1251)
Medtech (1253)
Mergers & acquisitions (9475)
Metabolic disorders (100)
Minnesota (37)
Neuroscience (374)
New Jersey (245)
New York (165)
NextGen Class of 2024 (1576)
Non-profit (588)
North Carolina (223)
Northern California (264)
Obesity (60)
Ohio (29)
Opinion (106)
Patents (40)
Pennsylvania (185)
People (28232)
Pharmaceutical (59)
Phase I (7820)
Phase II (12701)
Phase III (11412)
Pipeline (48)
Podcasts (35)
Policy (36)
Postmarket research (1398)
Preclinical (3127)
Press Release (25)
Rare diseases (51)
Real estate (2624)
Regulatory (9691)
Research institute (561)
Resumes & cover letters (55)
South America (496)
Southern California (264)
Startups (1623)
Texas (77)
United States (2625)
Vaccines (90)
Washington State (46)
Weight loss (52)
Date
Today (47)
Last 7 days (222)
Last 30 days (747)
Last 365 days (13333)
2024 (9276)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13890)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
258,918 Results for "adial pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals, Inc. today provided a business update and reported its financial results for the first quarter of 2024.
May 15, 2024
·
9 min read
BioCapital
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals, Inc. announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine.
June 20, 2024
·
6 min read
BioCapital
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
Adial Pharmaceuticals, Inc. today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.
April 22, 2024
·
4 min read
Business
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals, Inc. today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
April 2, 2024
·
10 min read
BioCapital
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.
May 29, 2024
·
2 min read
Business
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
·
4 min read
Press Releases
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
·
8 min read
BioCapital
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
Adial Pharmaceuticals, Inc. announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024.
February 15, 2024
·
5 min read
BioCapital
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office.
February 28, 2024
·
4 min read
BioCapital
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
Adial Pharmaceuticals, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term.
March 1, 2024
·
6 min read
1 of 25,892
Next
